Welcome to LookChem.com Sign In|Join Free

CAS

  • or

143901-35-3

Post Buying Request

143901-35-3 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

143901-35-3 Usage

Description

Aglafoline is a heterotricyclic compound with a unique chemical structure, characterized by a 2,3,3a,8b-tetrahydro-1H-benzo[b]cyclopenta[d]furan framework. It is substituted by hydroxy groups at positions C-1 and C-8b, a methoxycarbonyl group at C-2, a phenyl group at C-3, a 4-methoxyphenyl group at C-3a, and methoxy groups at C-6 and C-8. Aglafoline is a platelet aggregation inhibitor that can be found in Aglaia elliptifolia and Aglaia odorata.

Uses

Used in Pharmaceutical Industry:
Aglafoline is used as a platelet aggregation inhibitor for its ability to prevent blood clot formation. This property makes it a valuable compound in the development of medications aimed at treating conditions related to blood clotting, such as stroke, heart attack, and deep vein thrombosis.
Used in Research Applications:
Aglafoline is used as a research tool for studying the mechanisms of platelet aggregation and blood clotting. Its unique chemical structure and biological activity make it an important compound for understanding the underlying processes and developing new therapeutic strategies.
Used in Drug Discovery:
Aglafoline's platelet aggregation inhibiting properties make it a potential candidate for drug discovery in the development of new medications targeting blood clot-related disorders. Its chemical structure can be further modified and optimized to enhance its efficacy and selectivity, leading to the creation of more effective drugs.

Check Digit Verification of cas no

The CAS Registry Mumber 143901-35-3 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,4,3,9,0 and 1 respectively; the second part has 2 digits, 3 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 143901-35:
(8*1)+(7*4)+(6*3)+(5*9)+(4*0)+(3*1)+(2*3)+(1*5)=113
113 % 10 = 3
So 143901-35-3 is a valid CAS Registry Number.
InChI:InChI=1/C28H28O8/c1-32-18-12-10-17(11-13-18)28-23(16-8-6-5-7-9-16)22(26(30)35-4)25(29)27(28,31)24-20(34-3)14-19(33-2)15-21(24)36-28/h5-15,22-23,25,29,31H,1-4H3/t22-,23-,25-,27+,28+/m1/s1

143901-35-3SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 18, 2017

Revision Date: Aug 18, 2017

1.Identification

1.1 GHS Product identifier

Product name aglafolin

1.2 Other means of identification

Product number -
Other names -

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:143901-35-3 SDS

143901-35-3Related news

PAF antagonism in vitro and in vivo by aglafoline (cas 143901-35-3) from Aglaia elliptifolia Merr07/14/2019

Aglafoline, isolated from Aglaia elliptifolia Merr, inhibited in a selective and concentration-dependent manner the aggregation and ATP release reaction induced in washed rabbit platelets by PAF (platelet-activating factor). The IC50 values of aglafoline, BN52021 and kadsurenone on PAF (3.6 nM)-...detailed

143901-35-3Relevant articles and documents

Biomimetic kinetic resolution: Highly enantio- and diastereoselective transfer hydrogenation of aglain ketones to access flavagline natural products

Stone, Steven D.,Lajkiewicz, Neil J.,Whitesell, Luke,Hilmy, Ahmed,Porco, John A.

supporting information, p. 525 - 530 (2015/01/30)

We have previously reported asymmetric syntheses and absolute configuration assignments of the aglains (+)-ponapensin and (+)-elliptifoline and proposed a biosynthetic kinetic resolution process to produce enantiomeric rocaglamides and aglains. Herein, we

Synthetic silvestrol analogues as potent and selective protein synthesis inhibitors

Liu, Tao,Nair, Somarajan J.,Lescarbeau, Andre,Belani, Jitendra,Peluso, Stephane,Conley, James,Tillotson, Bonnie,OHearn, Patrick,Smith, Sherri,Slocum, Kelly,West, Kip,Helble, Joseph,Douglas, Mark,Bahadoor, Adilah,Ali, Janid,McGovern, Karen,Fritz, Christian,Palombella, Vito J.,Wylie, Andrew,Castro, Alfredo C.,Tremblay, Martin R.

, p. 8859 - 8878,20 (2020/09/16)

Misregulation of protein translation plays a critical role in human cancer pathogenesis at many levels. Silvestrol, a cyclopenta[b]benzofuran natural product, blocks translation at the initiation step by interfering with assembly of the eIF4F translation complex. Silvestrol has a complex chemical structure whose functional group requirements have not been systematically investigated. Moreover, silvestrol has limited development potential due to poor druglike properties. Herein, we sought to develop a practical synthesis of key intermediates of silvestrol and explore structure-activity relationships around the C6 position. The ability of silvestrol and analogues to selectively inhibit the translation of proteins with high requirement on the translation-initiation machinery (i.e., complex 5′-untranslated region UTR) relative to simple 5′UTR was determined by a cellular reporter assay. Simplified analogues of silvestrol such as compounds 74 and 76 were shown to have similar cytotoxic potency and better ADME characteristics relative to those of silvestrol.

ASYMMETRIC SYNTHESIS OF ROCAGLAMIDES VIA ENANTIOSELECTIVE PHOTOCYCLOADDITION MEDIATED BY CHIRAL BRONSTED ACIDS

-

Page/Page column 49, (2008/06/13)

The present invention provides a new strategies for the synthesis of compounds of the rocaglamide family and related natural products. The synthetic approach generally involves photochemical generation of an oxidopyrylium species from a 3-hydroxychromone derivative followed by an enantioselective 1,3-dipolar cycloaddition of the oxidopyrylium species to a dipolarophile in the presence of a TADDOL derivative. This approach can be used for the formation of adducts containing an aglain core structure. Methods of the conversion of aglain core structures to aglain, rocaglamide and forbaglin ring systems are also provided. The present invention also relates to the use of rocaglamide/aglain/forbaglin derivatives for the manufacture of medicaments for use in the treatment of cancer or cancerous conditions, disorders associated with cellular hyperproliferation, or NF-κB-dependent conditions.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 143901-35-3
  • ©2008 LookChem.com,License:ICP NO.:Zhejiang16009103 complaints:service@lookchem.com
  • [Hangzhou]86-571-87562588,87562561,87562573 Our Legal adviser: Lawyer